David W. C. MacMillan

David W. C. MacMillan
North Lanarkshire Council · OGL 3 · source
Name	David W. C. MacMillan
Birth date	1968
Birth place	Bellshill, North Lanarkshire
Nationality	British
Fields	Organic chemistry, asymmetric catalysis, organocatalysis
Workplaces	University of Edinburgh; California Institute of Technology; Princeton University
Alma mater	University of Glasgow; University of Edinburgh; University of California, Berkeley
Known for	Development of organocatalysis, asymmetric synthesis
Awards	Nobel Prize in Chemistry (2021); Tetrahedron Prize; Arthur C. Cope Scholar Award

David W. C. MacMillan is a Scottish chemist noted for pioneering contributions to asymmetric catalysis and the development of organocatalysis. He has held faculty positions at the University of Edinburgh, the California Institute of Technology, and Princeton University, and shared the Nobel Prize in Chemistry for 2021 with Benjamin List for the development of asymmetric organocatalysis. His work transformed approaches in organic chemistry and influenced research and industrial practice across pharmaceutical industry, materials science, and fine chemical synthesis.

Early life and education

MacMillan was born in Bellshill, North Lanarkshire, and raised amid the cultural settings of Glasgow and Scotland. He completed undergraduate studies at the University of Glasgow and pursued doctoral research at the University of Edinburgh under advisors active in organic synthesis and physical organic chemistry. Following his doctoral work, he undertook postdoctoral research at the University of California, Berkeley and engaged with research groups connected to leaders such as Barry M. Trost and E.J. Corey through academic networks and conferences, which shaped his early interests in catalytic methods and asymmetric transformations. These formative links to institutions like Imperial College London and ETH Zurich were reflected in collaborations and visiting scientist interactions.

Research and scientific career

MacMillan established an independent research program that emphasized small-molecule catalysis and stereocontrolled bond formation. At the University of Edinburgh and later at the California Institute of Technology and Princeton University, his group developed chiral imidazolidinone catalysts, initiating a practical platform for enantioselective transformations. His innovations connected to prior themes from investigators such as William S. Knowles, Ryoji Noyori, and K. Barry Sharpless in asymmetric catalysis, while charting a distinct path alongside contemporaries like Benjamin List, E. N. Jacobsen, and Scott E. Denmark. MacMillan’s methodology enabled enantioselective Diels–Alder reactions, Michael additions, and α-functionalizations via iminium and enamine activation modes, complementing metal-catalyzed and biocatalytic strategies developed at institutions such as Harvard University, Stanford University, and Columbia University.

His laboratory’s mechanistic studies intertwined experiments and spectroscopic techniques developed by groups at Max Planck Institute', University of California, Los Angeles, and Massachusetts Institute of Technology, elucidating transition states and stereochemical models that informed catalyst design. Collaborative projects linked MacMillan’s team to researchers at Pfizer, Novartis, and Roche for application-driven optimization and to national funding agencies including National Science Foundation and Engineering and Physical Sciences Research Council for basic research support.

Nobel Prize and major awards

The 2021 Nobel Prize in Chemistry, awarded jointly to MacMillan and Benjamin List, recognized their independent development of asymmetric organocatalysis, a milestone comparable in impact to earlier laureates such as Herbert C. Brown and Yves Chauvin. MacMillan’s recognition included major prizes like the Tetrahedron Prize, the Arthur C. Cope Scholar Award, and election to academies such as the Royal Society and the National Academy of Sciences. These honors mirrored historic awards given to figures like Roald Hoffmann and John C. Polanyi for transformative contributions to chemical science.

Teaching and mentorship

MacMillan’s teaching roles encompassed undergraduate and graduate instruction at Princeton University and outreach through symposia hosted by organizations such as the American Chemical Society and the Royal Society of Chemistry. He supervised doctoral students and postdoctoral fellows who later joined faculties at institutions including University of Cambridge, Yale University, University of California, Berkeley, University of Chicago, and industrial research groups at Merck and GlaxoSmithKline. His mentorship emphasized rigorous mechanistic reasoning and synthetic creativity, fostering a global network of researchers who continue work in fields linked to asymmetric synthesis, catalysis, and methodology development.

Industrial applications and entrepreneurship

MacMillan’s organocatalytic methods found rapid uptake in pharmaceutical process chemistry and agrochemical development at companies such as AstraZeneca, Eli Lilly and Company, and Bristol-Myers Squibb, supporting enantioselective routes to active pharmaceutical ingredients and intermediates. He engaged in translational initiatives and co-founded startups and partnerships to commercialize catalyst platforms and enable scalable asymmetric processes, collaborating with venture entities connected to Silicon Valley and technology transfer offices at Princeton University and Caltech. These efforts paralleled industrial adoption of catalytic innovations exemplified by collaborations between DuPont and academic groups for sustainable synthesis.

Selected publications and contributions

MacMillan’s representative contributions include original reports on imidazolidinone-catalyzed enantioselective transformations, reviews synthesizing organocatalysis concepts, and mechanistic papers clarifying activation modes. Key articles were published in journals such as Nature, Science, Journal of the American Chemical Society, Angewandte Chemie International Edition, and Chemical Reviews, and were cited alongside foundational works by George Olah, Robert H. Grubbs, and Richard R. Schrock. His body of work advanced practical asymmetric methods, inspired derivative catalyst designs, and established organocatalysis as a mainstream strategy in synthetic planning, complementing biocatalysis studies at Scripps Research and metal-catalyzed asymmetric protocols developed at Columbia University and ETH Zurich.

Category:Scottish chemists Category:Nobel laureates in Chemistry Category:Organic chemists